Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review

Background: The landscape of systemic therapies for advanced non-melanoma skin cancers has been revolutionized by the advent of immunotherapy. Cemiplimab is the only immune checkpoint inhibitor (ICI) approved by the European Medicine Agency for recurrent/metastatic cutaneous squamous cell carcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Banini, Marco, Salvestrini, Viola, Vultaggio, Alessandra, Perlato, Margherita, Mecheri, Valentina, Cerbai, Cecilia, Scotti, Vieri, Matucci, Andrea, Mangoni, Monica, Livi, Lorenzo, Bonomo, Pierluigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378378/
https://www.ncbi.nlm.nih.gov/pubmed/37504351
http://dx.doi.org/10.3390/curroncol30070491

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378378/
https://www.ncbi.nlm.nih.gov/pubmed/37504351
http://dx.doi.org/10.3390/curroncol30070491

Ejemplares similares